Mayra Ramos

1.3k total citations
33 papers, 827 citations indexed

About

Mayra Ramos is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mayra Ramos has authored 33 papers receiving a total of 827 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mayra Ramos's work include HER2/EGFR in Cancer Research (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Mayra Ramos is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Monoclonal and Polyclonal Antibodies Research (9 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Mayra Ramos collaborates with scholars based in Cuba, Spain and Mexico. Mayra Ramos's co-authors include Tania Crombet, Rolando Pérez, Olga Torres, Agustín Lage, Normando Iznaga-Escobar, I. Leonard, René Figueredo, Eduardo Fernández, Normando Iznaga and Teresa Cruz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Oncotarget.

In The Last Decade

Mayra Ramos

31 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mayra Ramos Cuba 16 461 297 268 180 112 33 827
Olga Torres Cuba 8 374 0.8× 230 0.8× 177 0.7× 140 0.8× 104 0.9× 12 595
Minghuan Li China 17 368 0.8× 494 1.7× 216 0.8× 117 0.7× 49 0.4× 46 912
Dianna Shipley United States 20 724 1.6× 453 1.5× 92 0.3× 283 1.6× 61 0.5× 68 1.1k
S. Huang United States 5 712 1.5× 540 1.8× 172 0.6× 376 2.1× 52 0.5× 9 1.1k
Ritesh Rathore United States 15 837 1.8× 242 0.8× 221 0.8× 217 1.2× 21 0.2× 44 1.0k
Austin Doyle United States 15 423 0.9× 311 1.0× 94 0.4× 413 2.3× 38 0.3× 33 1.0k
Anne Beaven United States 19 511 1.1× 121 0.4× 87 0.3× 186 1.0× 170 1.5× 89 956
W. Mai United States 9 155 0.3× 397 1.3× 141 0.5× 148 0.8× 103 0.9× 35 708
R O Dillman United States 14 648 1.4× 706 2.4× 291 1.1× 151 0.8× 64 0.6× 23 1.2k
Yasir Y. Elamin United States 16 595 1.3× 518 1.7× 62 0.2× 284 1.6× 32 0.3× 68 968

Countries citing papers authored by Mayra Ramos

Since Specialization
Citations

This map shows the geographic impact of Mayra Ramos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayra Ramos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayra Ramos more than expected).

Fields of papers citing papers by Mayra Ramos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mayra Ramos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayra Ramos. The network helps show where Mayra Ramos may publish in the future.

Co-authorship network of co-authors of Mayra Ramos

This figure shows the co-authorship network connecting the top 25 collaborators of Mayra Ramos. A scholar is included among the top collaborators of Mayra Ramos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mayra Ramos. Mayra Ramos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saavedra, Danay, et al.. (2022). Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody. Immunology Letters. 251-252. 1–8. 2 indexed citations
2.
Figueredo, Carlos Marcelo, Mayra Ramos, Danay Saavedra, et al.. (2021). An Anti-CD6 Antibody for the Treatment of COVID-19 Patients with Cytokine-Release Syndrome: Report of Three Cases. Immunotherapy. 13(4). 289–295. 8 indexed citations
3.
Crombet, Tania, et al.. (2021). Reposicionamiento del anticuerpo monoclonal humanizado anti-CD6 itolizumab en el tratamiento de pacientes con COVID-19. SHILAP Revista de lepidopterología.
4.
Viada, Carmen, et al.. (2020). Evaluación de la calidad de vida como predictor de supervivencia en el cáncer. Bionatura. 5(3). 1223–1292.
5.
Viada, Carmen, et al.. (2020). Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. Bionatura. 5(1). 1056–1062. 1 indexed citations
6.
Ramos, Mayra, Danay Saavedra, Zaima Mazorra, et al.. (2020). Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19. Gerontology. 66(6). 553–561. 22 indexed citations
7.
8.
Saavedra, Danay, Armando Caballero, Carmen Valenzuela, et al.. (2020). An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immunity & Ageing. 17(1). 34–34. 18 indexed citations
9.
Mazorra, Zaima, et al.. (2018). Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology. 45(1-2). 18–26. 51 indexed citations
10.
Blanco, Rancés, et al.. (2017). Double Expression of Epidermal Growth Factor Receptor and N-Glycolyl GM3 Ganglioside in Human Malignant Tumors: A Study in Four Different Clinical Scenarios. 2017(1). 1–6. 1 indexed citations
11.
Cetina, Lucely, Tania Crombet, Mayra Ramos, et al.. (2015). A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biology & Therapy. 16(5). 684–689. 19 indexed citations
12.
Viada, Carmen, et al.. (2013). Pharmacokinetics Evaluation of Nimotuzumab in Combination with Doxorubicin and Cyclophosphamide in Patients with Advanced Breast Cancer. RECERCAT (Consorci de Serveis Universitaris de Catalunya). 2 indexed citations
13.
Rodríguez, Pedro C., Gil Reyes, M.V. Hernández, et al.. (2012). A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. PubMed. 2. 204–211. 33 indexed citations
14.
15.
Crombet, Tania, Mauricio Catalá, Mayra Ramos, et al.. (2006). Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biology & Therapy. 5(4). 375–379. 124 indexed citations
16.
Iznaga-Escobar, Normando, et al.. (2004). 99mTc-labeled murine ior C5 monoclonal antibody in colorectalcarcinoma patients: Pharmacokinetics, biodistribution, absorbedradiation doses to normal organs and tissues and tumor localization. Methods and Findings in Experimental and Clinical Pharmacology. 26(9). 687–687. 6 indexed citations
17.
Vallis, Katherine A., Raymond M. Reilly, Amit M. Oza, et al.. (2002). A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nuclear Medicine Communications. 23(12). 1155–1164. 25 indexed citations
18.
Crombet, Tania, Olga Torres, Vanina Rodríguez, et al.. (2001). Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary Study. Hybridoma. 20(2). 131–136. 49 indexed citations
19.
Crombet, Tania, Olga Torres, Elia Neninger, et al.. (2001). Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody against Epidermal Growth Factor Receptor. Cancer Biotherapy and Radiopharmaceuticals. 16(1). 93–102. 21 indexed citations
20.
Ramos, Mayra, Nelson Rodríguez, Normando Iznaga-Escobar, et al.. (1999). 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.. PubMed. 40(5). 768–75. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olga Torres Breakdown of academic impact, for papers by Minghuan Li Breakdown of academic impact, for papers by Dianna Shipley Breakdown of academic impact, for papers by S. Huang Breakdown of academic impact, for papers by Ritesh Rathore Breakdown of academic impact, for papers by Austin Doyle Breakdown of academic impact, for papers by Anne Beaven Breakdown of academic impact, for papers by W. Mai Breakdown of academic impact, for papers by R O Dillman Breakdown of academic impact, for papers by Yasir Y. Elamin
Rankless by CCL
2026